• HCAR3 Cryo-EM Structures Explain Agonist Selectivity

  2026-08-22

  The 2025 PLOS Biology study resolves HCAR3–Gi complexes with four agonists and compares Acifran-bound HCAR3 and HCAR2, defining structural features that govern ligand recognition and receptor selectivity. Its combination of cryo-EM and cellular cAMP analysis provides a mechanistic framework for lipid signaling pathway modulation and for designing HCAR3-directed ligands with reduced HCAR2-linked liabilities.

• Antimycin A4: ATP-Citrate Lyase Inhibitor Workflow

  2026-08-21

  Antimycin A4 supports mechanism-focused studies that separate ATP-citrate lyase inhibition from mitochondrial respiratory-chain effects. This practical guide shows how to build biochemical, mitochondrial, and cellular workflows while controlling solvent, stability, substrate competition, and cytotoxicity confounders.

• Antipyrine: Recovery-Aware BBB Assay Design

  2026-08-20

  Antipyrine is a versatile research compound for connecting barrier transport, recovery, and pharmacokinetic interpretation. This article translates a 2025 surrogate BBB study into a practical, recovery-aware workflow for pain, fever, CNS, and drug metabolism research.

• 3-Deazaadenosine hydrochloride for m6A Studies

  2026-08-20

  Use 3-Deazaadenosine hydrochloride as a time-controlled SAHH perturbant to test whether methyl-metabolism changes influence the IGF2BP1–TUBB4B pathway in hepatic stellate cells. This workflow combines concentration-response profiling, RNA-stability measurements, pathway readouts, and genetic controls to separate broad methylation effects from target-specific biology.

• Astrocytic GAT-3 Shapes Dentate Gyrus Memory

  2026-08-19

  The reference study identifies astrocytic GAT-3 as an active regulator of dentate gyrus synaptic transmission, linking GABA uptake to astrocytic Ca2+ signaling, presynaptic GluN2B-containing NMDA receptor activity, and contextual fear memory. Its combined electrophysiological, optogenetic, anatomical, calcium-signaling, and behavioral approach provides a framework for investigating glial control of hippocampal circuits.

• 3X FLAG Peptide for Isoform-Aware Assays

  2026-08-19

  The 3X (DYKDDDDK) Peptide can strengthen detection, purification, and structural workflows when epitope accessibility is treated as an experimental variable. This article connects FLAG-tag assay design with the context-dependent biology revealed by DPF2 alternative splicing.

• Astrocytic GAT-3 Regulates DG Memory and Synapses

  2026-08-18

  The reference study identifies astrocytic GAT-3 as an active regulator of dentate gyrus synaptic transmission rather than merely a GABA clearance transporter. Its experiments connect GAT-3-dependent astrocytic Ca2+ signaling, presynaptic GluN2B-containing NMDARs, and contextual fear memory, providing a mechanistic framework for studying astrocyte–neuron control of hippocampal circuits.

• FH1 and the Next Era of Hepatocyte Maturation

  2026-08-18

  Functional maturity is the translational bottleneck in many iPS-derived hepatocyte workflows. This thought-leadership article examines how the FH1 small molecule can strengthen hepatocyte-like cell performance, how to validate that phenotype rigorously, and what regulated gene-expression systems may contribute to the next generation of liver research platforms.

• Carvedilol Phosphate: From GPCR Signaling to Liver IRI

  2026-08-17

  A translational perspective on using Carvedilol Phosphate to interrogate adrenergic signaling alongside the hepatocyte Arrb2–6-ketoLCA–macrophage axis identified in hepatic ischemia–reperfusion injury. The article translates mechanistic evidence into practical study design while distinguishing established pharmacology from emerging hypotheses.

• IGF2BP1–TUBB4B Signaling in Hepatic Stellate Cells

  2026-08-17

  The reference study identifies IGF2BP1 as an m6A reader that promotes hepatic stellate cell activation by stabilizing TUBB4B mRNA and engaging FAK signaling. Its integrated sequencing, genetic perturbation, and pharmacological experiments define a mechanistic axis relevant to liver fibrosis while also clarifying how methylation-focused assays should be interpreted.

• Intracellular Photocatalytic NADH Oxidation in Cancer

  2026-08-16

  The 2025 JACS Perspective frames intracellular NADH/NAD(P)H oxidation as a catalytic mechanism for photocatalytic cancer therapy rather than a conventional stoichiometric drug effect. By comparing metal-based photocatalysts, redox readouts, and cellular constraints, it identifies metabolic selectivity as a promising but still preclinical design objective.

• Honokiol-Induced Paraptosis in Acute Promyelocytic Leukemia

  2026-08-15

  Liu and colleagues showed that honokiol triggers paraptosis-like, rather than classically apoptotic, death in NB4 acute promyelocytic leukemia cells through oxidative stress, mitochondrial injury, endoplasmic reticulum stress, and mTOR/MAPK signaling. The study provides a mechanistic framework for evaluating nonapoptotic leukemia-cell death while highlighting the need for pathway-specific validation beyond LC3 or p62 accumulation alone.

• 2-APB (2-aminoethoxydiphenyl borate) for Cell Assays

  2026-08-14

  This scenario-based guide explains how 2-APB (2-aminoethoxydiphenyl borate), SKU B6643, can help researchers separate calcium-dependent effects from vehicle, assay, and cell-death artifacts. It covers concentration selection, compatibility, interpretation, and practical vendor evaluation for viability, proliferation, and cytotoxicity workflows.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody

  2026-08-14

  This affinity-purified Cy3-conjugated secondary antibody supports fluorescence-based detection of rabbit IgG primary antibodies in immunofluorescence, IHC, ICC, and flow cytometry workflows. It is intended for research use only and should not be used for diagnostic, medical, or unvalidated live-cell applications.

• Ibrexafungerp Activity Against Resistant Candida auris

  2026-08-13

  The reference study evaluated ibrexafungerp against 54 Candida auris isolates and tested delayed oral treatment in a neutropenic mouse model of invasive candidiasis. Its central finding was that activity was retained against fluconazole-resistant C. auris, while higher ibrexafungerp doses improved survival and reduced kidney fungal burden after therapy was initiated 24 hours after infection.

8276 records 1/552 page Next 12345 下5页 Last page